| 查看: 1550 | 回复: 4 | ||
[求助]
求助，大侠们，帮忙查一下USP35里面的celecoxib，着急啊谢谢
|
| 我的邮箱是zkx0928@126.com，先谢谢啦 |
回复此楼» 猜你喜欢
26考博申请 学or专
已经有15人回复
-
巴黎萨克雷大学与国家留学基金委合作博士研究生项目-脂质纳米药物/生物材料/多酚递送
已经有10人回复
-
药理学论文润色/翻译怎么收费?
已经有294人回复
-
锦州医科大学药用生物材料（专业代码1007Z1）招收调剂考生
已经有0人回复
-
锦州医科大学药用生物材料（专业代码1007Z1）招收调剂考生
已经有2人回复
-
26申博自荐
已经有12人回复
-
SUES&NERCN课题组接受硕士生调剂 (学硕1名+专硕1名)
已经有0人回复
-
SUES&NERCN课题组接受硕士生调剂 (学硕1名+专硕1名)
已经有0人回复
-
SUES&NERCN课题组接受硕士生调剂 (学硕1名+专硕1名)
已经有0人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 求教：博后申请中外国教授发来email要求发送些学位文件请大家帮忙确认一下
已经有16人回复
- 请高手帮忙翻译一段话 谢谢了！我英语很烂。。
已经有3人回复
- 高手进来帮帮忙
已经有3人回复
- 帮忙翻译一下摘要啊
已经有1人回复
- 跪求能用微谱数据库的虫子们，帮忙查一下碳谱数据，本人送6个金币！！！
已经有7人回复
- 帮忙分析下ASPEN PLUS 11.1中的这个错误报告
已经有10人回复
- 用过偏光显微镜的大侠请进
已经有7人回复
- 麻烦帮忙翻译哈下面这句话啊，把它翻译为英语，谢谢！
已经有6人回复
- 自觉发热证，请虫友们帮忙…
已经有6人回复
- 加一个碳。。。。帮忙一下 谢谢大侠们
已经有5人回复
- 求助SRIM中文教程
已经有3人回复
- 求助：投稿了4个月，今天收到了一封奇怪的邮件。请大侠们帮忙分析一下
已经有16人回复
- 【求助】MS中dmol3模块——两种分子的共吸附优化
已经有9人回复
- 【求助】申请荷兰大学的虫子们进来啊，帮帮忙分析下外导的意思，谢谢哈！！！！
已经有23人回复
痴夷子皮
版主 (文坛精英)
老痞
- DRDEPI: 8
- 应助: 2016 (讲师)
- 贵宾: 5.368
- 金币: 54487.3
- 散金: 41688
- 红花: 303
- 沙发: 1206
- 帖子: 32611
- 在线: 4303.7小时
- 虫号: 674536
- 注册: 2008-12-14
- 性别: GG
- 专业: 无神论
- 管辖: 人文社科
【答案】应助回帖
★ ★ ★
感谢参与，应助指数 +1
从头开始: 金币+3 2012-04-11 11:25:02
感谢参与，应助指数 +1
从头开始: 金币+3 2012-04-11 11:25:02
|
Add the following: Celecoxib (sel'' e kox' ib). C17H14F3N3O2S 381.4 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; p-[5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide [169590-42-5]. DEFINITION Celecoxib contains NLT 98.0% and NMT 102.0% of C17H14F3N3O2S, calculated on the anhydrous basis. IDENTIFICATION • A. Infrared Absorption 197: [Note—Methods 197A, 197K, or 197M under Infrared Absorption may be used. ] [Note—If the spectra obtained show differences, dissolve the substance to be examined and the Reference Standard separately in isopropyl alcohol, evaporate to dryness, and record the new spectra. ] • B. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay. ASSAY • Procedure Buffer: 2.7 g/L of monobasic potassium phosphate adjusted with phosphoric acid to a pH of 3.0 ± 0.2 Mobile phase: Methanol, acetonitrile, and Buffer (3:1:6) Diluent: Methanol and water (3:1) System suitability solution: 0.5 mg/mL of USP Celecoxib RS and 2.4 µg/mL each of USP Celecoxib Related Compound A RS and USP Celecoxib Related Compound B RS in Diluent Standard solution: 0.5 mg/mL of USP Celecoxib RS in Diluent Sample solution: 0.5 mg/mL of Celecoxib in Diluent Chromatographic system (See Chromatography 621, System Suitability.) Mode: LC Detector: UV 215 nm Column: 4.6-mm × 25-cm; 5-µm packing L11 Column temperature: 60 Flow rate: 1.5 mL/min Injection size: 25 µL Run time: About 1.5 times the celecoxib peak elution System suitability Samples: System suitability solution and Standard solution Suitability requirements Resolution: NLT 1.8 between celecoxib related compound A and celecoxib and NLT 1.8 between celecoxib and celecoxib related compound B, System suitability solution Relative standard deviation: NMT 0.73%, Standard solution Analysis Samples: Standard solution and Sample solution Calculate the percentage of C17H14F3N3O2S in the portion of Celecoxib taken: Result = (rU/rS) × (CS/CU) × 100 rU = = peak response from the Sample solution rS = = peak response from the Standard solution CS = = concentration of the Standard solution (mg/mL) CU = = concentration of the Sample solution (mg/mL) Acceptance criteria: 98.0%–102.0% on the anhydrous basis IMPURITIES Inorganic Impurities • Heavy Metals: NMT 20 ppm Diluent: Acetone and water (17:3) Standard solution: Dilute 1.0 mL of Standard Lead Solution, prepared as directed under Heavy Metals 231, Special Reagents, with Diluent to 20 mL. Sample solution: Dissolve 0.50 g of Celecoxib in 20 mL of Diluent. Blank solution: 20 mL of Diluent Analysis Samples: Standard solution, Blank solution, and Sample solution To each solution, add 2 mL of pH 3.5 Acetate Buffer, prepared as directed under Heavy Metals 231, Method I. Mix, and add to each solution 1.2 mL of thioacetamide–glycerin base TS. Mix immediately, and allow to stand for 2 min. Pass the solutions through a filter of 0.45-µm pore size. Compare the spots on the filters obtained from each of the solutions. Acceptance criteria: The brownish-black color of the spot resulting from the Sample solution is not more intense than that of the spot resulting from the Standard solution. The test is invalid if the Standard solution does not show a brownish-black color compared to the Blank solution. • Residue on Ignition 281: NMT 0.2%, using a platinum crucible Organic Impurities • Procedure Buffer, Mobile phase, Diluent, System suitability solution, Sample solution, and Chromatographic system: Proceed as directed in the Assay. Standard solution: 0.5 µg/mL of USP Celecoxib RS in Diluent System suitability Samples: System suitability solution and Standard solution Suitability requirements Resolution: NLT 1.8 between celecoxib related compound A and celecoxib and NLT 1.8 between celecoxib and celecoxib related compound B, System suitability solution Signal-to-noise ratio: NLT 20, Standard solution Analysis Samples: Standard solution and Sample solution Calculate the percentage of each impurity in the portion of Celecoxib taken: Result = (rU/rS) × (CS/CU) × 100 rU = = peak response for each impurity in the Sample solution rS = = peak response of celecoxib in the Standard solution CS = = concentration of celecoxib in the Standard solution (mg/mL) CU = = concentration of Celecoxib in the Sample solution (mg/mL) Acceptance criteria Individual impurities: See Table 1. [Note—Disregard any impurity peak less than 0.05%. ]  SPECIFIC TESTS • Water Determination, Method I 921: NMT 0.5%, using a 400-mg sample ADDITIONAL REQUIREMENTS • Packaging and Storage: Preserve in tight containers, protected from light and moisture. Store at room temperature. • USP Reference Standards 11 USP Celecoxib RS p-[5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide. C17H14F3N3O2S 381.4 USP Celecoxib Related Compound A RS 4-[5-(3-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide. C17H14F3N3O2S 381.4 USP Celecoxib Related Compound B RS 4-[3-(4-Methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide. C17H14F3N3O2S 381.4 1S (USP35) Auxiliary Information— Please check for your question in the FAQs before contacting USP.  USP35–NF30 Supplement : No. 1 Page 5447 Pharmacopeial Forum: Volume No. 36(6) Page 1519 |
» 本帖已获得的红花（最新10朵）
wangyi85
2楼2012-04-10 16:49:16
痴夷子皮
版主 (文坛精英)
老痞
- DRDEPI: 8
- 应助: 2016 (讲师)
- 贵宾: 5.368
- 金币: 54487.3
- 散金: 41688
- 红花: 303
- 沙发: 1206
- 帖子: 32611
- 在线: 4303.7小时
- 虫号: 674536
- 注册: 2008-12-14
- 性别: GG
- 专业: 无神论
- 管辖: 人文社科
3楼2012-04-10 16:51:06
4楼2012-04-11 10:59:10
5楼2012-07-02 10:14:19
